Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2018 Filed Nov 20, 2018 22:48 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
Tax withholdingCommon Stock | 11,200 | $1.07 | $11,953.76 |
DisclosureSEC source: 0001209191-18-059500 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,993 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 2,257,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 2,538,185 shares of common stock. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:46 UTC |
KUSSMAN CRAIGChief Financial Officer
|
Tax withholdingCommon Stock | 14,720 | $1.07 | $15,710.66 |
DisclosureSEC source: 0001209191-18-059498 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,103 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in August 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,305,000 shares of common stock underlying outstanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 1,638,103 shares of common stock. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:45 UTC |
Gallant PaulGeneral Manager
|
Tax withholdingCommon Stock | 9,450 | $1.07 | $10,085.99 |
DisclosureSEC source: 0001209191-18-059496 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,519 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,036,667 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 1,257,186 shares of common stock. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:42 UTC |
CROUCH TAYLORDirector · CEO & President
|
Tax withholdingCommon Stock | 5,140 | $1.07 | $5,485.92 |
DisclosureSEC source: 0001209191-18-059491 · doc4.xml · nonDerivative · entry 1 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,544 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 4,038,212 shares of common stock underlying outstanding options held by Mr. Crouch; post-transaction Mr. Crouch continues to beneficially own or have a right to acquire 4,202,756 shares of common stock. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:40 UTC |
Bush JenniferGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 11,915 | $1.07 | $12,716.88 |
DisclosureSEC source: 0001209191-18-059489 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,588 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,614,921 shares of common stock. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 22:17 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
SaleCommon Stock | 40,000 | $1.27 | $50,800.00 |
DisclosureSEC source: 0001209191-18-058330 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,193 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: This number does not include 2,257,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 2,549,385 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 23:03 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
Tax withholdingCommon Stock | 11,655 | $1.11 | $12,907.91 |
DisclosureSEC source: 0001209191-18-047204 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,193 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 2,257,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 2,589,385 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 23:01 UTC |
Gallant PaulGeneral Manager
|
Tax withholdingCommon Stock | 9,835 | $1.11 | $10,892.26 |
DisclosureSEC source: 0001209191-18-047200 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,969 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,036,667 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 1,266,636 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 23:02 UTC |
KUSSMAN CRAIGChief Financial Officer
|
Tax withholdingCommon Stock | 15,320 | $1.11 | $16,966.90 |
DisclosureSEC source: 0001209191-18-047201 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,823 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in August 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1.305,000 shares of common stock underlying outstanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 1,652,823 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 23:00 UTC |
CROUCH TAYLORDirector · CEO & President
|
Tax withholdingCommon Stock | 5,350 | $1.11 | $5,925.13 |
DisclosureSEC source: 0001209191-18-047197 · doc4.xml · nonDerivative · entry 1 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,684 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 4,038,212 shares of common stock underlying outstanding options held by Mr. Crouch; post-transaction Mr. Crouch continues to beneficially own or have a right to acquire 4,207,896 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 22:58 UTC |
Bush JenniferGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 12,400 | $1.11 | $13,733.00 |
DisclosureSEC source: 0001209191-18-047195 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,503 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,626,836 shares of common stock. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:03 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-18-047204 · doc4.xml · derivative · entry 2 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2028-08-15 F3 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:02 UTC |
KUSSMAN CRAIGChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-18-047201 · doc4.xml · derivative · entry 2 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2028-08-15 F3 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:00 UTC |
CROUCH TAYLORDirector · CEO & President
|
GrantStock Option (right to Buy) · Derivative | 1,350,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-18-047197 · doc4.xml · derivative · entry 2 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 1,350,000 shares Expires 2028-08-15 F3 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 22:58 UTC |
Bush JenniferGeneral Counsel & Secretary
|
GrantStock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-18-047195 · doc4.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2028-08-15 F3 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 23:04 UTC |
Hughes Steven GeorgeChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 974,694 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-046894 · doc4.xml · derivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,694 Underlying: Common Stock · 974,694 shares Expires 2028-08-14 F2 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 23:04 UTC |
Hughes Steven GeorgeChief Medical Officer
|
GrantCommon Stock | 160,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046894 · doc4.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,714 F1 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. 25% of the RSUs vest and settle on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:58 UTC |
Maroun Richard EDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044422 · doc4.xml · derivative · entry 1 Maroun Richard E · CIK 0001364590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:56 UTC |
Malloy KirkDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044421 · doc4.xml · derivative · entry 1 Malloy Kirk · CIK 0001326794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:55 UTC |
KESSEL MARKDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044420 · doc4.xml · derivative · entry 1 KESSEL MARK · CIK 0001222013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:54 UTC |
HOWSON TAMAR DDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044419 · doc4.xml · derivative · entry 1 HOWSON TAMAR D · CIK 0001202286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:52 UTC |
GLOVER JAMES TDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044418 · doc4.xml · derivative · entry 1 GLOVER JAMES T · CIK 0001231175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:51 UTC |
Baltera Robert Jr.Director
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044417 · doc4.xml · derivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 21:00 UTC |
CROUCH TAYLORDirector · CEO & President
|
Tax withholdingCommon Stock | 15,490 | $1.43 | $22,194.07 |
DisclosureSEC source: 0001209191-18-039515 · doc4.xml · nonDerivative · entry 2 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,034 F2 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of a performance-based restricted stock units granting in April 2017, pursuant to the Reporting Person's agreement with the Issuer. F3 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $1.42 to $1.445. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: This number does not include 2,688,212 shares of common stock underlying outstanding options held by Mr. Crouch; post-transaction Mr. Crouch continues to beneficially own or have a right to acquire 2,863,246 shares of common stock. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:00 UTC |
CROUCH TAYLORDirector · CEO & President
|
GrantCommon Stock | 41,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039515 · doc4.xml · nonDerivative · entry 1 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,524 F1 · price: In April 2017, Mr. Crouch received a grant of performance-based restricted stock units for 208,822 shares of the Issuer's Common Stock which vest contingent upon the Issuer's achievement of financial performance metrics set by the Issuer's Compensation Committee. On June 22, 2018, the Issuer's Compensation Committee determined that certain financial performance criteria were satisfied, and as a result, Mr. Crouch had vested in 41,764 shares of Common Stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:44 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033927 · doc4.xml · derivative · entry 2 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:44 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
GrantCommon Stock | 74,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033927 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,848 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 1,582,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 1,926,040 shares of common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:42 UTC |
KUSSMAN CRAIGChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033925 · doc4.xml · derivative · entry 2 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:42 UTC |
KUSSMAN CRAIGChief Financial Officer
|
GrantCommon Stock | 74,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033925 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,143 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 630,000 shares of common stock underlying outstanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 993,143 shares of common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:39 UTC |
Gallant PaulGeneral Manager
|
GrantStock Option (Right to Buy) · Derivative | 266,667 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033921 · doc4.xml · derivative · entry 2 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,667 Underlying: Common Stock · 266,667 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:39 UTC |
Gallant PaulGeneral Manager
|
GrantCommon Stock | 66,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033921 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,804 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 586,667 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 826,471 shares of common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:37 UTC |
CROUCH TAYLORDirector · CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033918 · doc4.xml · derivative · entry 2 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:37 UTC |
CROUCH TAYLORDirector · CEO & President
|
GrantCommon Stock | 148,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033918 · doc4.xml · nonDerivative · entry 1 CROUCH TAYLOR · CIK 0001197086 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,760 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 2,688,212 shares of common stock underlying outstanding options held by Mr. Crouch; post-transaction Mr. Crouch continues to beneficially own or have a right to acquire 2,836,972 shares of common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:36 UTC |
Bush JenniferGeneral Counsel & Secretary
|
GrantStock Option (Right to Buy) · Derivative | 283,333 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033917 · doc4.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,333 Underlying: Common Stock · 283,333 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:36 UTC |
Bush JenniferGeneral Counsel & Secretary
|
GrantCommon Stock | 70,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033917 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,903 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 658,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 964,236 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:41 UTC |
KUSSMAN CRAIGChief Financial Officer
|
Tax withholdingCommon Stock | 11,720 | $1.66 | $19,479.81 |
DisclosureSEC source: 0001209191-18-031109 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,763 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in August 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 330,000 shares of common stock underlying oustanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 618,763 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:42 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
Tax withholdingCommon Stock | 8,325 | $1.66 | $13,836.98 |
DisclosureSEC source: 0001209191-18-031111 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,468 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,282,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 1,551,660 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:40 UTC |
Gallant PaulGeneral Manager
|
Tax withholdingCommon Stock | 6,890 | $1.66 | $11,451.87 |
DisclosureSEC source: 0001209191-18-031107 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,689 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 320,000 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 493,689 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:39 UTC |
Bush JenniferGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 9,160 | $1.66 | $15,224.84 |
DisclosureSEC source: 0001209191-18-031104 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,655 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 610,655 shares of common stock. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 13:54 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
Tax withholdingCommon Stock | 9,420 | $1.09 | $10,225.41 |
DisclosureSEC source: 0001209191-18-011103 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,793 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,282,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 1,559,985 shares of common stock. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 13:51 UTC |
Gallant PaulGeneral Manager
|
Tax withholdingCommon Stock | 7,820 | $1.09 | $8,488.61 |
DisclosureSEC source: 0001209191-18-011101 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,579 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 320,000 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 500,579 shares of common stock. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 13:53 UTC |
KUSSMAN CRAIGChief Financial Officer
|
Tax withholdingCommon Stock | 13,265 | $1.09 | $14,399.16 |
DisclosureSEC source: 0001209191-18-011102 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,483 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in August 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 330,000 shares of common stock underlying oustanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 630,483 shares of common stock. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 13:50 UTC |
Bush JenniferGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 10,365 | $1.09 | $11,251.21 |
DisclosureSEC source: 0001209191-18-011100 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,815 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 619,815 shares of common stock. Read SEC document |
| November 24, 2017 Filed Dec 4, 2017 14:00 UTC |
Murphy KeithFormer affiliate last filing
|
PurchaseCommon Stock | 200,500 | $1.49 | $299,346.50 |
DisclosureSEC source: 0001536583-17-000002 · primary_doc.xml · nonDerivative · entry 2 Murphy Keith · CIK 0001536583 · Former affiliate last filing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,373,673 Read SEC document |
| November 22, 2017 Filed Dec 4, 2017 14:00 UTC |
Murphy KeithFormer affiliate last filing
|
PurchaseCommon Stock | 135,000 | $1.50 | $201,960.00 |
DisclosureSEC source: 0001536583-17-000002 · primary_doc.xml · nonDerivative · entry 1 Murphy Keith · CIK 0001536583 · Former affiliate last filing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173,173 Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:49 UTC |
Presnell Sharon CollinsChief Scientific Officer
|
Tax withholdingCommon Stock | 5,860 | $1.47 | $8,615.37 |
DisclosureSEC source: 0001209191-17-061328 · doc4.xml · nonDerivative · entry 1 Presnell Sharon Collins · CIK 0001536585 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,213 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,282,192 shares of common stock underlying outstanding options held by Dr. Presnell; post-transaction Dr. Presnell beneficially owns or has a right to acquire 1,569,405 shares of common stock. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:47 UTC |
Gallant PaulGeneral Manager
|
Tax withholdingCommon Stock | 7,015 | $1.47 | $10,313.45 |
DisclosureSEC source: 0001209191-17-061325 · doc4.xml · nonDerivative · entry 1 Gallant Paul · CIK 0001651405 · General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,399 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 320,000 shares of common stock underlying outstanding options held by Mr. Gallant; post-transaction Mr. Gallant beneficially owns or has a right to acquire 508,399 shares of common stock. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:48 UTC |
KUSSMAN CRAIGChief Financial Officer
|
Tax withholdingCommon Stock | 11,890 | $1.47 | $17,480.68 |
DisclosureSEC source: 0001209191-17-061327 · doc4.xml · nonDerivative · entry 1 KUSSMAN CRAIG · CIK 0001197083 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,748 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in August 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 330,000 shares of common stock underlying oustanding options held by Mr. Kussman; post-transaction Mr. Kussman continues to beneficially own or have a right to acquire 643,748 shares of common stock. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:46 UTC |
David EricCSO & EVP Pre-Clinical Dev
|
Tax withholdingCommon Stock | 5,625 | $1.47 | $8,269.88 |
DisclosureSEC source: 0001209191-17-061324 · doc4.xml · nonDerivative · entry 1 David Eric · CIK 0001549671 · CSO & EVP Pre-Clinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,609 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,070,000 shares of common stock underlying outstanding options held by Dr. David; post-transaction Dr. David beneficially owns or has a right to acquire 1,946,609 shares of common stock. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:45 UTC |
Bush JenniferGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 8,900 | $1.47 | $13,084.78 |
DisclosureSEC source: 0001209191-17-061322 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,180 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 630,180 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.